46 days ago
OptiBiotix Health (OPTI) has announced it has appointed Graham Myers as part-time Finance Director “to support the focus on driving each business unit and the group to profitability”. With it also added that “the appointment reflects the progress we have made in 2023 after a difficult 2022”, we look for the prospective trading news to boost the shares from a current 26.25p, below £24 million market capitalisation. Having an FD is part of growing up as a company and we welcome this big time.
82 days ago
OptiBiotix Health (OPTI) has issued a “Commercial update” announcement including that it is “seeing sales with existing partners improve month on month” and “strong” big new customers progress.
94 days ago
OptiBiotix Health (OPTI) has announced a license agreement to incorporate Tata Chemicals’ proprietary short chain fructo-oligosaccharide Fossence into its SlimBiome and LeanBiome for the Indian market.
179 days ago
OptiBiotix Health (OPTI) has issued a “Commercial update” announcement, noting commercial progress of its first-generation products range and reiterating plans for each business unit to reach operational profitability by the end of this year. What of this with the shares currently responding up towards 30p?
265 days ago
A “TR-1” (shareholding) announcement on the holding of Optibiotix Health (OPTI) in SkinBioTherapeutics (SBTX). So what’s this news?
517 days ago
On developer of “compounds to tackle obesity, cardiovascular disease and diabetes”, OptiBiotix Health (OPTI) we’ve previously noted ‘some delays in delivery but a sales recovery Buy’ – including with “product launches by Apollo Pharmacies in India and restocking by some partners with sales normalising… as in previous years, there was no contribution in this period from licence or royalty payments which tend to be received in the second half”. We’ve since again spoken to CEO Steve O’Hara.
576 days ago
Previously writing on OptiBiotix Health (OPTI), earlier this month we noted prior delays in delivery from larger deals but that orders are already coming through and being booked as second half sales. Now some clear evidence of this with an announcement that the company’s GoFigure meal replacement shakes and powdered beverage shots have now been officially launched by India’s Apollo Hospitals & Pharmacies.
641 days ago
Writing on OptiBiotix Health (OPTI) last month with the shares at 21p to buy, we noted potential for a move into meaningful profitability and further potential from ‘second generation’ products addressing much larger market opportunities. We drank our own medicine with Tom buying more shares at 22p. The shares are now further up at 31.5p on the back of a “Joint development agreement signed with Firmenich”-titled announcement.
821 days ago
OptiBiotix Health (OPTI) was one of our tips of the year, with we anticipating financial progress as its deals for its compounds expand and further deals kick-in. It has now announced that a further human volunteer study on its cholesterol-reducing probiotic LPLDL - on a different population group of hypercholesterolemic adults – has shown “at six weeks, when volunteers taking placebo were compared to those taking LPLDL, there were statistically significant changes to clinically important cardiovascular risk”, including “34.2% reduction in total cholesterol (p=0.001)”.
864 days ago
OptiBiotix Health (OPTI) has announced the launch of a new sports nutrition product range, LeanBiome, with a supply & licensing agreement with “a leading global player in beauty & nutrition”. What of a current share price response up to 42.5p?
936 days ago
Life sciences compounds developer OptiBiotix Health (OPTI) has announced results for the first of calendar 2021, emphasising “sales of LPLDL and SlimBiome of £1.076m, a 44.5% increase over H1:2020… pleasing given the continued uncertain global economic environment and challenges of the subsequent waves of COVID-19, particularly in countries like India and the USA”. The shares have currently responded slightly higher, to 50p.
1289 days ago
OptiBiotix Health (OPTI) “announces the launch of meal replacement shakes and bars containing OptiBiotix’s OptiBiome® proprietary weight management technology under the Optislim® brand with Woolworths, Chemist Warehouse and on OptiPharm Pty Ltd’s online store in Australia and New Zealand”…
1291 days ago
OptiBiotix Health (OPTI) is “pleased to have signed an agreement with UITC to distribute CholBiomeX3 in Singapore”…
1419 days ago
More news from OptiBiotix Health (OPTI) and we’re also asked to clarify re. previous statements by the company…
1420 days ago
Currently compounds to tackle obesity, high cholesterol and diabetes developer, OptiBiotix Health (OPTI) has announced results for the 13 months to 31st December 2019 (having moved its year-end from November), emphasising it “has met a significant number of important objectives that continue to build value for shareholders”. The shares have currently responded a bit lower to 62p, but the numbers are historic and look at the trading trajectory now…
1439 days ago
OptiBiotix Health (OPTI) has updated including noting first quarter of 2020 sales of £407,844 – and the shares have responded 11% higher to above 60p. Capitalising the company at around £53 million, why you may ask? Well, look at the company’s trajectory…
1446 days ago
OptiBiotix Health (OPTI) has announced “a non-exclusive license agreement for its SlimBiome® trademark with Smart For Life, Inc. and related launch of cookies containing OptiBiotix’s SlimBiome® proprietary weight management technology in the USA and Canada”…
1531 days ago
OptiBiotix Health (OPTI) has announced “a significant milestone” in extension of the use of its LPLDL probiotic strain into functional foods and its presence into South America. So what you say?
1569 days ago
OptiBiotix Health (OPTI) has announced a first agreement with a major retailer for its SlimBiome® functional ingredient with a product range to be initially sold in the UK, Republic of Ireland, Netherlands, Belgium and Sweden by health food chain Holland & Barrett…
1629 days ago
It has been announced OptiBiotix Health (OPTI) has sold 2.2 million further shares in 2017 spun-off onto AIM SkinBioTherapeutics (SBTX). This despite OptiBiotix’s results earlier this year including “SkinBiotherapeutics plc is making solid progress… As its partnership discussions turn into commercial agreements providing industry validation of its technology we anticipate SkinBiotherapeutics plc will grow in value, whereupon OptiBiotix shareholders will benefit from the appreciation of this asset”. So why the further sale?
1660 days ago
OptiBiotix Health (OPTI) has updated investors with news including “completing Pharmaceutical GMP process validation and receiving the GRAS notification letter from the US FDA is a significant achievement for ProBiotix and LPLDL®. Few marketed probiotics have achieved this level of proven safety and efficacy and it has triggered another milestone payment in the US Pharmaceutical agreement”…
1754 days ago
OptiBiotix (OPTI) has announced another license agreement to we loyal shareholders. This one is for the use of its ProBiotix’s LPLDL ingredient in cardiovascular food supplements in Japan and is set to mean a first LPLDL finished product placement on the Japanese market…
1781 days ago
More positive news from OptiBiotix Health (OPTI)?… The company has announced an exclusive license agreement for the commercialisation of, currently fully-owned subsidiary, ProBiotix’s cholesterol management products CholBiome and CholBiomex3 in Vietnam…
1935 days ago
OptiBiotix Health (OPTI) has announced that it has entered into an exclusive manufacturing and supply agreement with Zeon Lifesciences. The agreement grants Zeon an exclusive license to manufacture and supply OptiBiotix's SlimBiome weight management technology in India, in return for 50% of the profit.
2024 days ago
Having reached circa 130p in August, shares in OptiBiotix Health (OPTI) have slid to 78p-81p. This is despite a pipeline of seemingly very significant deals likely to be converted and as such…
